FDA
-
-
-
-
-
-
-
Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
-
-
-
-
-
-
-
miRagen Therapeutics (MGEN) Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
-
-
-
-
-
-
-
miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
-
-
-
-
-
-
-
miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

